• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Thermo Fisher expands gene therapy portfolio

July 8, 2021 By Sean Whooley

Thermo FisherThermo Fisher Scientific (NYSE:TMO) announced a new set of solutions to support adeno-associated viral (AAV) manufacturing.

AAV, a non-pathogenic virus capable of infecting cells at various stages of growth, has become a preferred “viral vector” for delivering gene therapies, although the scalability of AAV remains a challenge.

According to a news release, Thermo Fisher designed its new media panel, gene kit and advanced purification process to produce higher quality viral vectors, simplify the purification process and result in higher yield AAV production.

The Gibco viral vector HEK media panel covers a variety of HEK293 cell types, Thermo Fisher said, with no ties to specific transfection reagents or techniques. Its ready-to-use formulations can help AAV developers identify an optimal formulation for the target cell line.

Applied Biosystems’ resDNASEQ quantitative plasmid DNA kanamycin resistance gene kit offers an all-in-one option for the precise and rapid measurement of residual plasmid DNA, including a highly sensitive multiplex qPCR assay with all reagents and optimized sample prep options to deliver results in under five hours.

Finally, Thermo Fisher’s Poros CaptureSelect AAV affinity purification resins, the latest addition to a portfolio of viral vector solutions, can improve downstream processing of viral vectors through the reduction of purification steps while offering scalability.

“Despite the immense promise of gene therapy, robustness and yield continue to pose challenges in the manufacturing process,” Thermo Fisher Scientific VP & GM of cell & gene therapy Betty Woo said in the release. “Growth media that maximizes viral titer and rapid analytical tests contribute to cost-effective and efficient AAV production. Our expanding gene therapy portfolio is designed for a smooth ramp-up to clinical production and we have made focused investments to ensure we stay ahead of commercial demand.

“Ultimately, our innovative solutions are developed to expedite the delivery of safer therapies to patients.”

Filed Under: Business/Financial News, Featured, Immunotherapy, Pharmaceuticals Tagged With: thermofisherscientific

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS